Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $175 from $169 and keeps an Equal Weight rating on the shares. Following what it calls a “generally in line” Q3 report, with Pharma ahead of expectations and Medtech below and 2025 commentary that was “largely consistent with expectations,” the firm notes it made “modest adjustments” to its estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $185 from $180 at Citi
- Johnson & Johnson price target raised to $166 from $163 at Wells Fargo
- Bridgeport jury determines J&J to pay $15M over talc-based powder
- Johnson & Johnson price target raised to $170 from $160 at Stifel
- Legend Biotech weakness a buying opportunity, says Barclays